Late-Onset Pompe's Disease

Abstract

Glycogen storage disease type II, also known as Pompe's disease or acid maltase deficiency, is caused by a deficiency in acid α-glucosidase. Severe enzyme deficiency results in infantile Pompe's disease with multiorgan involvement; a partial deficiency produces a less severe phenotype mainly consisting of a myopathy, with a later age of onset. Treatment is now available with intravenous infusion of recombinant acid α-glucosidase. Such treatment results in marked improvement in patients with infantile Pompe's disease, and modest improvement or stabilization in patients with late-onset Pompe's disease.

Keywords

Pompe's disease - acid maltase deficiency - lysosomal storage disease - glycogen storage disease type II

• Reference

• 1 Chien YH, Chiang SC, Zhang XK , et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 2008; 122 (1) e39-e45
• 2 Ausems MG, Verbiest J, Hermans MP , et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 1999; 7 (6) 713-716
• 3 Ausems MG, Lochman P, van Diggelen OP, Ploos van Amstel HK, Reuser AJ, Wokke JH. A diagnostic protocol for adult-onset glycogen storage disease type II. Neurology 1999; 52 (4) 851-853
• 4 Martiniuk F, Chen A, Mack A , et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 1998; 79 (1) 69-72
• 5 Raben N, Takikita S, Pittis MG , et al. Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand... Autophagy 2007; 3 (6) 546-552
• 6 Winkel LP, Hagemans ML, van Doorn PA , et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol 2005; 252 (8) 875-884
• 7 Hagemans ML, Winkel LP, Van Doorn PA , et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005; 128 (Pt 3) 671-677
• 8 Yanovitch TL, Casey R, Banugaria SG, Kishnani PS. Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease. J Neuroophthalmol 2010; 30 (2) 165-166
• 9 Sacconi S, Bocquet JD, Chanalet S, Tanant V, Salviati L, Desnuelle C. Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease. J Neurol 2010; 257 (10) 1730-1733
• 10 Barohn RJ, McVey AL, DiMauro S. Adult acid maltase deficiency. Muscle Nerve 1993; 16 (6) 672-676
• 11 van der Ploeg AT. Monitoring of pulmonary function in Pompe disease: a muscle disease with new therapeutic perspectives. Eur Respir J 2005; 26 (6) 984-985
• 12 Berger KI, Skrinar A, Norman RG , et al. Ventilatory dysfunction in late-onset Pompe disease. Proc Am Thorac Soc 2005; 171: A788
• 13 Schoser BG, Müller-Höcker J, Horvath R , et al. Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited. Neuropathol Appl Neurobiol 2007; 33 (5) 544-559
• 14 Kishnani PS, Steiner RD, Bali D , et al. Pompe disease diagnosis and management guideline. Genet Med 2006; 8 (5) 267-288
• 15 Pichiecchio A, Uggetti C, Ravaglia S , et al. Muscle MRI in adult-onset acid maltase deficiency. Neuromuscul Disord 2004; 14 (1) 51-55
• 16 Kallwass H, Carr C, Gerrein J , et al. Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots. Mol Genet Metab 2007; 90 (4) 449-452
• 17 Mutations in human acid alpha-glucosidase. Pompe Center. Available at: www.pompe.com/en/healthcare-professionals/genetics-epidemiology/mutations.aspx . Accessed February 1, 2013
• 18 Van den Hout JM, Reuser AJ, de Klerk JB, Arts WF, Smeitink JA, Van der Ploeg AT. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 2001; 24 (2) 266-274
• 19 Kishnani PS, Corzo D, Nicolino M , et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007; 68 (2) 99-109
• 20 Amalfitano A, Bengur AR, Morse RP , et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001; 3 (2) 132-138
• 21 Van den Hout JM, Kamphoven JH, Winkel LP , et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004; 113 (5) e448-e457
• 22 Winkel LP, Van den Hout JM, Kamphoven JH , et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 2004; 55 (4) 495-502
• 23 van der Ploeg AT, Clemens PR, Corzo D , et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010; 362 (15) 1396-1406
• 24 Cupler EJ, Berger KI, Leshner RT , et al; AANEM Consensus Committee on Late-onset Pompe Disease. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 2012; 45 (3) 319-333
• 25 Genzyme Corporation. Lumizyme ACE Program. Available at: http://www.lumizyme.com/healthcare/lumizyme_ace_program.aspx . Accessed May 2, 2012
• 26 Mellies U, Ragette R, Schwake C, Baethmann M, Voit T, Teschler H. Sleep-disordered breathing and respiratory failure in acid maltase deficiency. Neurology 2001; 57 (7) 1290-1295
• 27 Mellies U, Stehling F, Dohna-Schwake C, Ragette R, Teschler H, Voit T. Respiratory failure in Pompe disease: treatment with noninvasive ventilation. Neurology 2005; 64 (8) 1465-1467
• 28 Laforêt P, Doppler V, Caillaud C , et al. Rigid spine syndrome revealing late-onset Pompe disease. Neuromuscul Disord 2010; 20 (2) 128-130
• 29 Brooke MH, Fenichel GM, Griggs RC , et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 1989; 39 (4) 475-481
• 30 Granata C, Merlini L, Cervellati S , et al. Long-term results of spine surgery in Duchenne muscular dystrophy. Neuromuscul Disord 1996; 6 (1) 61-68
• 31 van den Berg LE, Zandbergen AA, van Capelle CI , et al. Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density. Bone 2010; 47 (3) 643-649
• 32 Schoser B, Hill V, Raben N. Therapeutic approaches in glycogen storage disease type II/Pompe Disease. Neurotherapeutics 2008; 5 (4) 569-578
• 33 Bernstein DL, Bialer MG, Mehta L, Desnick RJ. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Mol Genet Metab 2010; 101 (2–3) 130-133